Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011069334 - CDK5 INHIBITORS AND THERAPEUTIC USES THEREOF

Publication Number WO/2011/069334
Publication Date 16.06.2011
International Application No. PCT/CN2010/001982
International Filing Date 07.12.2010
IPC
C07H 3/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
3Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
04Disaccharides
C07H 13/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
13Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
02by carboxylic acids
08having the esterifying carboxyl radicals directly attached to carbocyclic rings
C07D 311/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
311Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02ortho- or peri-condensed with carbocyclic rings or ring systems
04Benzo pyrans, not hydrogenated in the carbocyclic ring
06with oxygen or sulfur atoms directly attached in position 2
08not hydrogenated in the hetero ring
A61K 31/352 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/7016 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7016Disaccharides, e.g. lactose, lactulose
CPC
A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/7004
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7004Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7016
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7016Disaccharides, e.g. lactose, lactulose
A61K 31/7048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin ; digitoxin or digoxin
Applicants
  • THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY [CN]/[CN] (AllExceptUS)
  • IP, Nancy Yuk-Yu [CN]/[CN] (UsOnly)
  • IP, Fanny Chui-Fun [CN]/[CN] (UsOnly)
  • FU, Wing Yu [CN]/[CN] (UsOnly)
  • FU, Guangmiao [CN]/[CN] (UsOnly)
Inventors
  • IP, Nancy Yuk-Yu
  • IP, Fanny Chui-Fun
  • FU, Wing Yu
  • FU, Guangmiao
Agents
  • BEIJING KINSCOM INTELLECTUAL PROPERTY AGENT CO., LTD.
Priority Data
61/282,03907.12.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CDK5 INHIBITORS AND THERAPEUTIC USES THEREOF
(FR) INHIBITEURS DE LA CDK5 ET LEURS UTILISATIONS THÉRAPEUTIQUES
Abstract
(EN)
Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.
(FR)
Les inhibiteurs naturels de la protéine kinase 5 cycline-dépendante (Cdk5), isolés de la racine de Rhodiola rosea, sont structurellement différents des inhibiteurs connus des Cdk. Ils présentent une sélectivité pour les différentes Cdk et se révèlent efficaces à inhiber les Cdk par un mécanisme d'inhibition mixte, ce qui devrait entraîner moins de toxicité et d'effets secondaires. Ils peuvent être utilisés dans le cadre de la prévention et du traitement des maladies et affections associées à une activité aberrante de la Cdk5, par exemple la douleur aiguë et/ou chronique, la douleur névropathique, le diabète sucré, le cancer, les maladies neurodégénératives et les troubles neuropathologiques.
Also published as
GB1211237.1
Latest bibliographic data on file with the International Bureau